GLP-1 Blood Test Monitoring: What to Actually Track on Ozempic, Wegovy, and Mounjaro

You have been on the weekly injection for five months. The scale has moved. But some days you feel flat by mid-afternoon, hair is coming out in the shower, and your GP's last panel said everything looks fine. GLP-1 medications shift your metabolism, liver, kidneys, and nutritional status simultaneously, and a standard yearly check-up was not designed to catch changes moving at that speed. Here is what to actually monitor, and why each marker matters.

Is the medication doing what it should? The metabolic response markers

Three markers tell you whether GLP-1 therapy is shifting your glucose control in the right direction, and whether your pancreas is genuinely off the hook or still working overtime in the background.

HbA1c (glycated hemoglobin) reflects your average blood sugar across the past three months. It does not spike or dip with your last meal, so it captures the trend rather than the moment. In the phase 3 STEP 1 trial of once-weekly semaglutide 2.4 mg, adults lost a mean of around 15 percent of body weight over 68 weeks with parallel improvements in glycemic status and HbA1c (Wilding et al., 2021). Two-year data show the effect held without meaningful rebound during continued treatment (Garvey et al., 2022).

Fasting Insulin is the underappreciated one. Glucose can look perfectly normal while the pancreas is working overtime to keep it there. Fasting insulin shows you the effort behind the reading. When GLP-1 therapy is working properly, insulin falls alongside glucose, not in place of it.

HOMA-Index (Homeostatic Model Assessment of Insulin Resistance, or HOMA-IR) combines Glucose and Insulin readings (both measured fasted) into a single insulin-resistance score. It is the marker most sensitive to metabolic direction. If HbA1c is drifting down but HOMA-Index stays high, your pancreas is still under strain and the picture is not as clean as the scale suggests.

The markers that drift before you notice: nutritional status on GLP-1

When appetite drops and meal volume shrinks, certain micronutrients fall below requirements quietly, well before the body shows obvious signs. In a large retrospective cohort of adults with type 2 diabetes who started GLP-1 therapy, around 12.7 percent were newly diagnosed with a nutritional deficiency within six months, rising to 22 percent by twelve months (Butsch et al., 2025). Vitamin D deficiency was the most common finding; iron and B vitamins followed.

Ferritin is the iron-stores marker that tends to fall first. Two mechanisms stack: you eat less iron-rich food, and semaglutide directly reduces intestinal iron absorption. A prospective pilot study measured oral iron absorption in the same patients before and after ten weeks of semaglutide, and found it dropped by around 13 percent (Melis et al., 2025). Registry data across adults with type 2 diabetes put GLP-1 users at 26 to 30 percent lower ferritin than users of other diabetes medications (Urbina et al., 2026). That matters because low ferritin shows up as fatigue, breathlessness on stairs, hair shedding, and restless legs long before a standard blood count flags anemia.

Vitamin D is already a challenge for most people across a Central European winter, and GLP-1 therapy tends to make the gap wider. Dietary analyses of GLP-1 users showed average vitamin D intake at around 20 percent of recommended levels (Urbina et al., 2026). During rapid weight loss, low Vitamin D accelerates bone thinning and contributes to muscle weakness.

Vitamin B12 drifts more slowly but steadily. Reduced appetite cuts animal-protein intake, and delayed gastric emptying affects how efficiently B12 is released and absorbed. The first symptoms, fatigue, brain fog, and tingling in the fingers or toes, are subtle enough that people tend to write them off as the body adjusting to treatment.

Liver health: why your baseline reading matters more than you think

Metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly known as NAFLD, non-alcoholic fatty liver disease), affects approximately 30 percent of adults globally, and most of them have no idea (Younossi et al., 2023). Starting a GLP-1 when you have undiagnosed MASLD means you cannot tell whether your liver is recovering, staying the same, or facing additional stress from rapid metabolic change.

The good news is that semaglutide tends to help the liver substantially. In the ESSENCE phase 3 trial of adults with confirmed MASH (the inflammatory form of MASLD) plus moderate to advanced liver scarring, 62.9 percent of the semaglutide group achieved resolution of liver inflammation at 72 weeks, compared with 34.3 percent on placebo (Sanyal et al., 2025). Earlier meta-analyses also showed meaningful reductions in the liver enzymes ALT and AST after 24 weeks of treatment (Bandyopadhyay et al., 2023).

But "tends to help" is a population statement. To know whether it is helping yours specifically, you need a baseline. That means ALT (liver cell turnover, leaning more liver-specific than AST), GGT (the only liver enzyme with essentially no muscle expression), and the FIB-4 Index, a calculated liver-stability score that combines age with two liver enzymes and platelet count to estimate fibrosis risk non-invasively.

Kidney function: why Cystatin C gives a cleaner reading than creatinine here

Standard kidney panels at the GP almost always lead with creatinine and the eGFR (estimated Glomerular Filtration Rate, a calculation of how well the kidneys are filtering blood) derived from it. That works fine when body composition is stable. During GLP-1 therapy, it stops being a clean signal.

Here is why. Creatinine is a waste product of muscle metabolism. The less muscle you carry, the less creatinine your body produces, and the lower your blood level looks, even if your kidneys are doing exactly the same job as before. Because GLP-1 therapy causes measurable muscle loss alongside fat loss, the standard creatinine reading can make kidney function appear to improve when nothing has actually changed.

Cystatin C sidesteps this entirely. It is filtered by the kidneys at a steady rate and produced by nearly every cell in the body, with no meaningful dependence on muscle mass. A post-hoc analysis of the SURPASS-4 trial confirmed that Cystatin C-based eGFR gives a more reliable kidney picture during weight loss than the creatinine version, and confirmed the kidney-protective effect of the GLP-1 class independent of muscle changes (Heerspink et al., 2023).

When to test and what to choose

A baseline before starting is ideal. If that was not possible, a test shortly after starting still creates a reference point. The first follow-up most useful at around three months: by then HbA1c and HOMA-Index should have moved, and ferritin or liver enzymes will show any early drift. After that, testing every six months captures the slower-moving changes in Vitamin D, B12, and kidney markers. Discuss the exact cadence with your prescribing doctor.

Metabolism Core is the practical entry point. It covers all four areas above: HbA1c, Glucose, Insulin, and HOMA-Index for metabolic response; Ferritin for iron stores; the full liver panel including FIB-4; and both creatinine-based eGFR and Cystatin C for a reliable kidney picture. Results in up to two working days.

For a deeper nutritional picture, Holistic Advanced adds Vitamin D, Vitamin B12, Holo-transcobalamin (the active fraction of B12 and a more sensitive early-warning marker), Vitamin B6, Vitamin B9, Vitamin B2, Magnesium in full blood, Cortisol, Zinc, Selenium, the full fatty acid panel including Omega-3 Index, and thyroid hormones. It is the panel for the first comprehensive follow-up, or for anyone who wants to see every nutritional system in one view. A relevant internal comparison: our guide on understanding liver values and metabolic markers covers the liver enzyme story in more depth, and our piece on glucose strategies explains the HbA1c and insulin context further.

GLP-1 blood test monitoring, frequently asked